SLC5A2 and chronic kidney disease: Future research should focus on optimizing NO–cGMP modulation in advanced CKD and HF patients, exploring novel sGC stimulators with improved safety profiles, combinatory regimens (e.g., with SGLT2 inhibitors) for synergistic cardiorenal protection, and identifying patient subgroups most likely to benefit without undue hypotensive risk.